[go: up one dir, main page]

WO2008145721A3 - N-terminal modification of polypeptides for protection against degradation by aminopeptidases - Google Patents

N-terminal modification of polypeptides for protection against degradation by aminopeptidases Download PDF

Info

Publication number
WO2008145721A3
WO2008145721A3 PCT/EP2008/056673 EP2008056673W WO2008145721A3 WO 2008145721 A3 WO2008145721 A3 WO 2008145721A3 EP 2008056673 W EP2008056673 W EP 2008056673W WO 2008145721 A3 WO2008145721 A3 WO 2008145721A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
aminopeptidases
protection against
against degradation
terminal modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/056673
Other languages
French (fr)
Other versions
WO2008145721A2 (en
Inventor
Ulrich Sensfuss
Frantisek Hubalek
Lauge Schaeffer
Thomas Hoeg-Jensen
Janos Tibor Kodra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of WO2008145721A2 publication Critical patent/WO2008145721A2/en
Publication of WO2008145721A3 publication Critical patent/WO2008145721A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/003—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by transforming the C-terminal amino acid to amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

N-terminally modified polypeptides comprising one or more N-terminal modifications consisting of an organic molecular substituent having a MW below 100 g per mol are ob- tained by the invention. Also compositions comprising such and the use thereof are com- prised by the invention.
PCT/EP2008/056673 2007-06-01 2008-05-30 N-terminal modification of polypeptides for protection against degradation by aminopeptidases Ceased WO2008145721A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109440 2007-06-01
EP07109440.3 2007-06-01

Publications (2)

Publication Number Publication Date
WO2008145721A2 WO2008145721A2 (en) 2008-12-04
WO2008145721A3 true WO2008145721A3 (en) 2009-03-12

Family

ID=38473104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/056673 Ceased WO2008145721A2 (en) 2007-06-01 2008-05-30 N-terminal modification of polypeptides for protection against degradation by aminopeptidases

Country Status (1)

Country Link
WO (1) WO2008145721A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009019027A (en) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin-secreting peptide derivatives with amino-terminal amino acid mutations
JP2013513622A (en) 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ Methods for inhibiting cataracts and presbyopia
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP2013540771A (en) * 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス Novel N-terminally modified insulin derivative
CN103596584B (en) 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 Polysubstituted insulin
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015502971A (en) * 2011-12-21 2015-01-29 ノヴォ ノルディスク アー／エス N-terminal modified insulin derivative
KR102198622B1 (en) * 2013-03-14 2021-01-05 유니버시티 오브 매사추세츠 Methods of inhibiting cataracts and presbyopia
AR099569A1 (en) 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
CN112494656B (en) 2014-11-21 2024-01-30 默沙东有限责任公司 Insulin receptor partial agonists
PE20181070A1 (en) 2015-11-13 2018-07-04 Univ Massachusetts BIFUNCTIONAL MOLECULES CONTAINING PEG FOR USE IN THE INHIBITION OF CATARACT AND PRESBYCIA
WO2018056764A1 (en) 2016-09-23 2018-03-29 한미약품 주식회사 Insulin analog having reduced binding force to insulin receptor, and use thereof
JP7604098B2 (en) 2017-03-23 2024-12-23 ハンミ ファーマシューティカル カンパニー リミテッド Conjugate of insulin analogue with reduced binding ability to insulin receptor and use thereof
AU2022210988B9 (en) 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
AU2022347024A1 (en) 2021-09-15 2024-05-02 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105677A2 (en) * 2002-06-01 2003-12-24 Praecis Pharmaceuticals, Inc. Methods for treating viral diseases using modulators of amyloidogenic peptide aggregation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105677A2 (en) * 2002-06-01 2003-12-24 Praecis Pharmaceuticals, Inc. Methods for treating viral diseases using modulators of amyloidogenic peptide aggregation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GLIEMANN J ET AL: "The biological activity and the binding affinity of modified insulins determined on isolated rat fat cells.", DIABETOLOGIA APR 1974, vol. 10, no. 2, April 1974 (1974-04-01), pages 105 - 113, XP002453103, ISSN: 0012-186X *
HINDS KEN ET AL: "Synthesis and characterization of poly(ethylene glycol)-insulin conjugates", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 11, no. 2, 15 February 2000 (2000-02-15), pages 195 - 201, XP002391407, ISSN: 1043-1802 *
UCHIO T ET AL: "Site-specific insulin conjugates with enhanced stability and extended action profile", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 35, no. 2-3, 1999, pages 289 - 306, XP002363507, ISSN: 0169-409X *

Also Published As

Publication number Publication date
WO2008145721A2 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
WO2008145721A3 (en) N-terminal modification of polypeptides for protection against degradation by aminopeptidases
PL2091987T3 (en) Coating agents having high scratch resistance and weathering stability
WO2007101698A3 (en) Modified molecules which promote hematopoiesis
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
MX2010003328A (en) Cell-permeabilising peptides and polypeptides for microbial cells.
WO2008121767A3 (en) Stitched polypeptides
WO2008046911A3 (en) Novel human micrornas associated with cancer
EP2548925A3 (en) Poly (block-phosphonato-ester) and poly (block-phosphonato-carbonate)
MX2009009900A (en) Dendritic polyurethane coating.
TW200643453A (en) Polymerizable composition comprising low molecular weight organic component
WO2008014008A3 (en) Compositions and methods for modulating angiogenesis
WO2007100574A3 (en) Biodegradable phosphoester polyamines
WO2006105387A8 (en) Oleds utilizing direct injection to the triplet state
WO2009058564A3 (en) Immunosuppressive polypeptides and nucleic acids
WO2009123969A3 (en) Deoxybenzoin-derived anti-flammable polymers
WO2006066024A3 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
WO2008118567A3 (en) Polythioether amine resins and compositions comprising same
WO2008104979A3 (en) Nuclear targeting sequences
WO2008078189A3 (en) Factor vii and viia compositions
WO2007023293A3 (en) Luminescent material compositions and structures incorporating the same
WO2006079076A3 (en) Yersinia spp. polypeptides and methods of use
WO2006103277A3 (en) 2 , 4 , 5-substituted piperidines as renin inhibitors
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
WO2006060189A3 (en) Curable silicone compositions incorporating a fluorescent detection system
EP2151463A3 (en) Alkylated aminopropylated methylene-di-(cyclohexylamine) and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08760263

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08760263

Country of ref document: EP

Kind code of ref document: A2